Efficacy and Tolerance of EGb 761 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-Blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70.

Trial Profile

Efficacy and Tolerance of EGb 761 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-Blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jan 2013

At a glance

  • Drugs EGb 761 (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Therapeutic Use
  • Acronyms GuidAge
  • Most Recent Events

    • 22 Jun 2010 Primary endpoint 'Disease occurrence' has not been met, according to an Ipsen media release of top-line results.
    • 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Planned end date changed from 1 Jan 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov record (NCT00276510).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top